(NASDAQ: CMPX) Compass Therapeutics's forecast annual revenue growth rate of 417.45% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Compass Therapeutics's revenue in 2025 is $850,000.On average, 1 Wall Street analysts forecast CMPX's revenue for 2025 to be $1,700,874,725, with the lowest CMPX revenue forecast at $1,700,874,725, and the highest CMPX revenue forecast at $1,700,874,725. On average, 7 Wall Street analysts forecast CMPX's revenue for 2026 to be $2,885,955,733, with the lowest CMPX revenue forecast at $525,473,492, and the highest CMPX revenue forecast at $6,117,617,712.
In 2027, CMPX is forecast to generate $17,580,268,818 in revenue, with the lowest revenue forecast at $5,351,532,673 and the highest revenue forecast at $31,641,801,192.